SEC Form 4

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

	NOVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSH	TATEMENT	EMENT OF C	HANGES IN	BENEFICIAL	OWNERSHI
--	----------	------------	-----------	-------------------	-----------------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								1								
1. Name and Address of Reporting Person [*] Burow Kristina					2. Issuer Name and Ticker or Trading Symbol <u>Neumora Therapeutics, Inc.</u> [NMRA]							tionship of Reportir all applicable) Director	ng Perso X	on(s) to I 10% C		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/22/2023							Officer (give title below)		Other below)	(specify	
8755 W. HIGGINS ROAD,SUITE 1025				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)											Х	Form filed by One	e Repor	ting Per	son	
CHICAGO	IL	60631									Form filed by More than One Reporting Person					
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication												
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			-	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Disposed Of			d 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Own Form: (D) or I (I) (Insi	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									(A) or	Duin 1		Transaction(s)				

	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transa Code (8)		Disposed Of	(D) (Inst	r. 3, 4 and 5)	Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	09/22/2023		р		40,000	А	\$11.14 ⁽¹⁾	3,664,143	I	By ARCH Venture Fund XII, L.P. (4)(5)
Common Stock	09/25/2023		Р		30,773	A	\$10.8 ⁽²⁾	3,694,916	I	By ARCH Venture Fund XII, L.P. (4)(5)
Common Stock	09/25/2023		Р		29,967	A	\$11.65 ⁽³⁾	3,724,883	I	By ARCH Venture Fund XII, L.P. (4)(5)
Common Stock								13,620	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	f Expiration Date (Month/Day/Year) (Month/Day/Year) (Source) (Month/Day/Year) (Month/Day/Year) (Source)		Expiration Date (Month/Day/Year) vurities vurities vor posed D) D)			of Expiration Date Derivative (Month/Day/Year) Securities Acquired				e and Int of rities rlying ative rity (Instr. 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares									

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$10.50 to \$11.48, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1),(2), and (3) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$10.50 to \$11.49, inclusive.

3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$11.50 to \$12.14, inclusive.

4. Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ACH XII. ARCH Venture Partners XII, L.P. (AVP XII LL) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC) to be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

5. As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.

Kristina Burow, Managing Director, By: /s/ Mark 09/25/2023

McDonnell, as Attorney-in-Fact

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.